Synergistic inhibitory effects of the oxyresveratrol and dacarbazine combination against melanoma cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Sang Gyu | - |
dc.contributor.author | Lee, Dong Gun | - |
dc.contributor.author | Joo, Yong Hoon | - |
dc.contributor.author | Chung, Namhyun | - |
dc.date.accessioned | 2022-02-21T19:42:37Z | - |
dc.date.available | 2022-02-21T19:42:37Z | - |
dc.date.created | 2022-02-09 | - |
dc.date.issued | 2021-09 | - |
dc.identifier.issn | 1792-1074 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/136418 | - |
dc.description.abstract | Various therapies have been developed to target malignant melanoma, which is associated with a high mortality rate worldwide. Although dacarbazine (DTIC) is employed for treating melanoma, it is associated with several side effects. Hence, patients with melanoma are co-treated with additional drugs to mitigate the side effects of DTIC. In the present study, synergistic therapeutic effects of the DTIC/oxyresveratrol (ORT) combination were examined using the human malignant melanoma WM-266-4 cell line. Treatment with ORT and DTIC inhibited the proliferation of WM-266-4 cells. Compared with those in the ORT- and DTIC-treated groups, the proportion of cells arrested at the S phase, as well as apoptotic rates, were increased in the ORT and DTIC co-treatment group. In WM-266-4 cells, synergistic proliferation-inhibitory activities of the ORT/DTIC combination were assessed based on cell viability and migration, antioxidant capacity, cytokine production, cell cycle arrest, apoptotic rate and protein expression through WST-1 assay, wound healing assay, flow cytometry and western blotting. Furthermore, the expression levels of proteins, including NOTCH, involved in the pathogenesis of solid cancers, such as melanoma, were examined. Overall, the ORT/DTIC combination synergistically promoted cell cycle arrest at the S phase and the apoptosis of WM-266-4 cells. Thus, this combination treatment may serve as a novel therapeutic strategy for treating malignant melanoma. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPANDIDOS PUBL LTD | - |
dc.subject | MALIGNANT-MELANOMA | - |
dc.subject | NITRIC-OXIDE | - |
dc.subject | C-MYC | - |
dc.subject | EXPRESSION | - |
dc.subject | APOPTOSIS | - |
dc.subject | BCL-2 | - |
dc.subject | INTERFERON-ALPHA-2B | - |
dc.subject | PROLIFERATION | - |
dc.subject | INTERLEUKIN-6 | - |
dc.subject | ACTIVATION | - |
dc.title | Synergistic inhibitory effects of the oxyresveratrol and dacarbazine combination against melanoma cells | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Chung, Namhyun | - |
dc.identifier.doi | 10.3892/ol.2021.12928 | - |
dc.identifier.scopusid | 2-s2.0-85110346126 | - |
dc.identifier.wosid | 000678470100001 | - |
dc.identifier.bibliographicCitation | ONCOLOGY LETTERS, v.22, no.3 | - |
dc.relation.isPartOf | ONCOLOGY LETTERS | - |
dc.citation.title | ONCOLOGY LETTERS | - |
dc.citation.volume | 22 | - |
dc.citation.number | 3 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | APOPTOSIS | - |
dc.subject.keywordPlus | BCL-2 | - |
dc.subject.keywordPlus | C-MYC | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | INTERFERON-ALPHA-2B | - |
dc.subject.keywordPlus | INTERLEUKIN-6 | - |
dc.subject.keywordPlus | MALIGNANT-MELANOMA | - |
dc.subject.keywordPlus | NITRIC-OXIDE | - |
dc.subject.keywordPlus | PROLIFERATION | - |
dc.subject.keywordAuthor | Notch signaling | - |
dc.subject.keywordAuthor | S phase arrest | - |
dc.subject.keywordAuthor | chemical drug | - |
dc.subject.keywordAuthor | stilbenoid | - |
dc.subject.keywordAuthor | synergistic effect | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.